Company Description
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States.
Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome.
In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths.
The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction.
BioCardia, Inc. is based in Sunnyvale, California.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Peter Altman |
Contact Details
Address: 320 Soquel Way Sunnyvale, California 94085 United States | |
| Phone | 650 226 0120 |
| Website | biocardia.com |
Stock Details
| Ticker Symbol | BCDA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000925741 |
| CUSIP Number | 09060U507 |
| ISIN Number | US09060U5074 |
| Employer ID | 23-2753988 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Peter Altman | Chief Executive Officer |
| David McClung | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 17, 2024 | 144 | Filing |
| Dec 17, 2024 | 8-K | Current Report |
| Dec 4, 2024 | 8-K | Current Report |
| Dec 2, 2024 | 424B5 | Filing |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Oct 28, 2024 | 8-K | Current Report |
| Sep 18, 2024 | 8-K | Current Report |
| Sep 9, 2024 | 8-K | Current Report |
| Sep 6, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |